Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) CFO Vaseem Mahboob sold 6,995 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.68, for a total value of $172,636.60. Following the completion of the transaction, the chief financial officer directly owned 86,896 shares in the company, valued at approximately $2,144,593.28. This represents a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Vaseem Mahboob also recently made the following trade(s):
- On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total value of $199,352.37.
- On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.75, for a total value of $90,545.00.
Kestra Medical Technologies Stock Performance
Shares of NASDAQ:KMTS traded up $0.21 on Thursday, reaching $25.27. The company’s stock had a trading volume of 184,867 shares, compared to its average volume of 393,651. The company has a 50-day simple moving average of $22.86 and a 200 day simple moving average of $22.54. Kestra Medical Technologies, Ltd. has a 52-week low of $14.10 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.
Institutional Investors Weigh In On Kestra Medical Technologies
A number of large investors have recently made changes to their positions in KMTS. Seven Grand Managers LLC acquired a new stake in Kestra Medical Technologies during the 4th quarter worth $2,652,000. Eventide Asset Management LLC raised its position in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies during the fourth quarter worth about $9,282,000. Finally, UBS Group AG boosted its position in Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after acquiring an additional 69,908 shares during the last quarter.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group cut their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $27.83.
View Our Latest Report on KMTS
Kestra Medical Technologies Company Profile
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Stories
- Five stocks we like better than Kestra Medical Technologies
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
